Product Description
SAR103168 is a novel multi-targeted kinase inhibitor administered via intravenous infusion and active in various acute myeloid leukemia (AML) models including immature CD34+ AML cells expressing functional P-glycoprotein (P-gp). (Sourced from: https://ncats.nih.gov/files/SAR103168.pdf)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00981240 |
TED10416 | P1 |
Completed |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia |
2012-01-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|